A novel rapamycin analog is highly selective for mTORC1 in vivo

Rapamycin, an inhibitor of mechanistic Target Of Rapamycin Complex 1 (mTORC1), extends lifespan and shows strong potential for the treatment of age-related diseases. However, rapamycin exerts metabolic and immunological side effects mediated by off-target inhibition of a second mTOR-containing complex, mTOR complex 2. Here, we report the identification of DL001, a FKBP12-dependent rapamycin analog 40x more selective for mTORC1 than rapamycin. DL001 inhibits mTORC1 in cell culture lines and in vivo in C57BL/6J mice, in which DL001 inhibits mTORC1 signaling without impairing glucose homeostasis and with substantially reduced or no side effects on lipid metabolism and the immune system. In cells, DL001 efficiently represses elevated mTORC1 activity and restores normal gene expression to cells lacking a functional tuberous sclerosis complex. Our results demonstrate that highly selective pharmacological inhibition of mTORC1 can be achieved in vivo, and that selective inhibition of mTORC1 significantly reduces the side effects associated with conventional rapalogs. Rapamycin extends lifespan in model organisms by targeting mTORC1, but exerts off-target side effects via inhibition of mTORC2. Here, the authors report the identification of a selective mTORC1 inhibitor, and show that it inhibits mTORC1 activity both in vitro and in vivo, with reduced side effects on glucose homeostasis, lipid metabolism, and the immune system.

[1]  J. Clardy,et al.  Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A resolution. , 1999, Acta crystallographica. Section D, Biological crystallography.

[2]  J. Kovarik,et al.  Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[3]  D. Guertin,et al.  Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.

[4]  I. Gout,et al.  The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins , 2004, The Journal of cell biology.

[5]  C. Bodemer,et al.  Cutaneous Adverse Events in Renal Transplant Recipients Receiving Sirolimus-Based Therapy1 , 2005, Transplantation.

[6]  D. Kwiatkowski,et al.  Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. , 2005, Human molecular genetics.

[7]  Matt Kaeberlein,et al.  Extension of chronological life span in yeast by decreased TOR pathway signaling. , 2006, Genes & development.

[8]  D. Sabatini,et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.

[9]  P. Crino.  Focal brain malformations: a spectrum of disorders along the mTOR cascade. , 2007, Novartis Foundation symposium.

[10]  John C. Lawrence,et al.  Muscle-Specific Deletion of Rictor Impairs Insulin-Stimulated Glucose Transport and Enhances Basal Glycogen Synthase Activity , 2007, Molecular and Cellular Biology.

[11]  D. Sabatini,et al.  Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. , 2007, Blood.

[12]  Marco Pahor,et al.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice , 2009, Nature.

[13]  D. Sabatini,et al.  An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.

[14]  Qicheng Ma,et al.  Activation of a metabolic gene regulatory network downstream of mTOR complex 1. , 2010, Molecular cell.

[15]  D. Fingar,et al.  mTORC1 Inhibition via Rapamycin Promotes Triacylglycerol Lipolysis and Release of Free Fatty Acids in 3T3-L1 Adipocytes , 2010, Lipids.

[16]  Jayanta Debnath,et al.  Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease , 2010, PloS one.

[17]  L. Partridge,et al.  Mechanisms of Life Span Extension by Rapamycin in the Fruit Fly Drosophila melanogaster , 2010, Cell metabolism.

[18]  M. Magnuson,et al.  Fat Cell–Specific Ablation of Rictor in Mice Impairs Insulin-Regulated Fat Cell and Whole-Body Glucose and Lipid Metabolism , 2010, Diabetes.

[19]  Anne E Carpenter,et al.  mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway , 2011, Cell.

[20]  D. Rothstein,et al.  Regulatory T Cells Require Mammalian Target of Rapamycin Signaling To Maintain Both Homeostasis and Alloantigen-Driven Proliferation in Lymphocyte-Replete Mice , 2011, The Journal of Immunology.

[21]  D. Sabatini,et al.  The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling , 2011, Science.

[22]  M. Horton,et al.  Regulation of immune responses by mTOR. , 2012, Annual review of immunology.

[23]  Dudley Lamming,et al.  Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity , 2012, Science.

[24]  Kira Glover-Cutter,et al.  TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO. , 2012, Cell metabolism.

[25]  Maria A. Woodward,et al.  Rapamycin slows aging in mice , 2012, Aging cell.

[26]  A. Caccamo,et al.  Lifelong rapamycin administration ameliorates age‐dependent cognitive deficits by reducing IL‐1β and enhancing NMDA signaling , 2012, Aging cell.

[27]  Dudley Lamming,et al.  Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of mTORC1 and mTORC2 , 2012, Front. Gene..

[28]  Yuanyuan Wu,et al.  Insulin Inhibits Lipolysis in Adipocytes via the Evolutionarily Conserved mTORC1-Egr1-ATGL-Mediated Pathway , 2013, Molecular and Cellular Biology.

[29]  A. Bracher,et al.  Large FK506-Binding Proteins Shape the Pharmacology of Rapamycin , 2013, Molecular and Cellular Biology.

[30]  Dudley Lamming,et al.  Young and old genetically heterogeneous HET3 mice on a rapamycin diet are glucose intolerant but insulin sensitive , 2013, Aging cell.

[31]  L. Kappos,et al.  Rapamycin Attenuates the Progression of Tau Pathology in P301S Tau Transgenic Mice , 2013, PloS one.

[32]  Dudley Lamming,et al.  A Central role for mTOR in lipid homeostasis. , 2013, Cell metabolism.

[33]  Lan Ye,et al.  Rapalogs and mTOR inhibitors as anti-aging therapeutics. , 2013, The Journal of clinical investigation.

[34]  D. Krueger,et al.  Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma , 2013, Neurology.

[35]  D. Griffiths,et al.  Renal tumours in a Tsc2+/− mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin , 2014, Oncogene.

[36]  L. Luo,et al.  Genetic Deletion of Rheb1 in the Brain Reduces Food Intake and Causes Hypoglycemia with Altered Peripheral Metabolism , 2014, International journal of molecular sciences.

[37]  M. Smithey,et al.  Immune Memory–Boosting Dose of Rapamycin Impairs Macrophage Vesicle Acidification and Curtails Glycolysis in Effector CD8 Cells, Impairing Defense against Acute Infections , 2014, The Journal of Immunology.

[38]  Emma L. Baar,et al.  Depletion of Rictor, an essential protein component of mTORC2, decreases male lifespan , 2014, Aging cell.

[39]  J. Praestgaard,et al.  mTOR inhibition improves immune function in the elderly , 2014, Science Translational Medicine.

[40]  B. Kaplan,et al.  Strategies for the management of adverse events associated with mTOR inhibitors. , 2014, Transplantation reviews.

[41]  Dudley Lamming,et al.  Rapamycin-induced metabolic defects are reversible in both lean and obese mice , 2014, Aging.

[42]  M. MacCoss,et al.  Altered proteome turnover and remodeling by short-term caloric restriction or rapamycin rejuvenate the aging heart , 2014, Aging cell.

[43]  P. Froguel,et al.  Beneficial Metabolic Effects of Rapamycin Are Associated with Enhanced Regulatory Cells in Diet-Induced Obese Mice , 2014, PloS one.

[44]  T. Hornberger,et al.  A role for Raptor phosphorylation in the mechanical activation of mTOR signaling. , 2014, Cellular signalling.

[45]  Z. D. Sharp,et al.  Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction , 2014, Aging cell.

[46]  Qingyuan Zhang,et al.  Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. , 2015, The Lancet. Oncology.

[47]  D. Kwiatkowski,et al.  Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2 , 2015, European Journal of Human Genetics.

[48]  Katherine H. Schreiber,et al.  Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins , 2015, Aging cell.

[49]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[50]  B. Vergès,et al.  mTOR inhibitors and diabetes. , 2015, Diabetes research and clinical practice.

[51]  K. Limesand,et al.  Lifespan-extending caloric restriction or mTOR inhibition impair adaptive immunity of old mice by distinct mechanisms , 2014, Aging cell.

[52]  K. Kotulska,et al.  Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening , 2015, Anti-cancer drugs.

[53]  S. A. Arriola Apelo,et al.  Intermittent Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice. , 2016, The journals of gerontology. Series A, Biological sciences and medical sciences.

[54]  B. Kennedy,et al.  The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging. , 2016, Cell metabolism.

[55]  James C Yao,et al.  Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study , 2016, The Lancet.

[56]  A. Wilfong,et al.  Long-term treatment of epilepsy with everolimus in tuberous sclerosis , 2016, Neurology.

[57]  Christian M. Metallo,et al.  Adipose tissue mTORC2 regulates ChREBP-driven de novo lipogenesis and hepatic glucose metabolism , 2016, Nature Communications.

[58]  H. Guchelaar,et al.  Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer , 2016, Cancer Chemotherapy and Pharmacology.

[59]  S. Tardif,et al.  Pharmaceutical inhibition of mTOR in the common marmoset: effect of rapamycin on regulators of proteostasis in a non-human primate , 2016, Pathobiology of aging & age related diseases.

[60]  Kathleen F. Kerr,et al.  Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice , 2016, eLife.

[61]  S. A. Arriola Apelo,et al.  Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system , 2015, Aging cell.

[62]  D. James,et al.  Mammalian target of rapamycin complex 2 regulates muscle glucose uptake during exercise in mice , 2017, The Journal of physiology.

[63]  M. Dai,et al.  RHEB1 insufficiency in aged male mice is associated with stress-induced seizures , 2017, GeroScience.

[64]  D. James,et al.  mTORC2 regulates muscle glucose uptake during exercise in mice , 2017 .

[65]  K. Budde,et al.  Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study , 2017, PloS one.

[66]  D. Promislow,et al.  A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs , 2017, GeroScience.

[67]  Cuilan Yang,et al.  Rheb1 deletion in myeloid cells aggravates OVA-induced allergic inflammation in mice , 2017, Scientific Reports.

[68]  M. Beibel,et al.  TORC1 inhibition enhances immune function and reduces infections in the elderly , 2018, Science Translational Medicine.

[69]  T. Curiel,et al.  A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects , 2018, Experimental Gerontology.

[70]  S. A. Arriola Apelo,et al.  Restoration of metabolic health by decreased consumption of branched‐chain amino acids , 2017, The Journal of physiology.

[71]  Dudley Lamming,et al.  Next generation strategies for geroprotection via mTORC1 inhibition. , 2019, The journals of gerontology. Series A, Biological sciences and medical sciences.